AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Beale, Gary ^a   Chattopadhyay, Dipankar ^a   Gray, Joe ^a   Stewart, Stephen ^a   Hudson, Mark ^a   Day, Christopher ^a   Trerotoli, Paolo ^b   Giannelli, Gianluigi ^b   Manas, Derek ^a   Reeves, Helen ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; FOLLISTATIN; GLYPICAN 3; SQUAMOUS CELL CARCINOMA ANTIGEN; SQUAMOUS CELL CARCINOMA ANTIGEN 1; GLYPICAN; PROTEIN PRECURSOR; PROTHROMBIN; SERINE PROTEINASE INHIBITOR; SQUAMOUS CELL CARCINOMA RELATED ANTIGEN; SQUAMOUS CELL CARCINOMA-RELATED ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ALCOHOLIC FATTY LIVER; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SURVEILLANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; NONALCOHOLIC FATTY LIVER; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; VIRUS HEPATITIS; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; FATTY LIVER; GENETICS; INCIDENCE; LIVER TUMOR; MIDDLE AGED; PREGNANCY; SURVIVAL;

AGED; ALPHA-FETOPROTEINS; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; FATTY LIVER; FATTY LIVER, ALCOHOLIC; FEMALE; FOLLISTATIN; GLYPICANS; HUMANS; INCIDENCE; LIVER NEOPLASMS; MIDDLE AGED; PREGNANCY; PROTEIN PRECURSORS; PROTHROMBIN; SERPINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 48549106668     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-200     Document Type: Article

References (26)

1. Parkin DM Bray F Ferlay J Pisani P Estimating the world cancer burden: Globocan 2000 Int J Cancer 2001, 94(2):153-156. 10.1002/ijc.1440 11668491
2. Deuffic S Poynard T Buffat L Valleron AJ Trends in primary liver cancer Lancet 1998, 351(9097):214-215. 10.1016/S0140-6736(05)78179-4 9449893
3. Bosch FX Ribes J Diaz M Cleries R Primary liver cancer: Worldwide incidence and trends Gastroenterology 2004, 127(5 Suppl 1);S5-S16. 10.1053/j.gastro.2004.09.011 15508102
4. Bruix J Llovet JM Prognostic prediction and treatment strategy in hepatocellular carcinoma Hepatology 2002, 35(3):519-524. 10.1053/ jhep.2002.32089 11870363
5. Sherman M Alphafetoprotein: An obituary J Hepatol 2001, 34(4);603-605. 10.1016/S0168-8278(01)00025-3 11394662
6. Bruix J Sherman M Llovet JM Beaugrand M Lencioni R Burroughs AK Christensen E Pagliaro L Colombo M Rodes J Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 2001, 35(3):421-430. 10.1016/S0168-8278(01)00130-1 11592607
7. Liebman HA Furie BC Tong MJ Blanchard RA Lo KJ Lee SD Coleman MS Furie B Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma N Engl J Med 1984, 310(22):1427-1431. 6201741
8. Koike Y Shiratori Y Sato S Obi S Teratani T Imamura M Yoshida H Shiina S Omata M Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: A prospective analysis of 227 patients Cancer 2001, 91(3):561-569. 10.1002/ 1097-0142(20010201)91:3<561::AID-CNCR1035>3.0.CO;2-N 11169939
9. Hagiwara S Kudo M Kawasaki T Nagashima M Minami Y Chung H Fukunaga T Kitano M Nakatani T Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma J Gastroenterol 2006, 41(12):1214-1219. 10.1007/s00535-006-1950-7 17287901
10. Suehiro T Sugimachi K Matsumata T Itasaka H Taketomi A Maeda T Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein Cancer 1994, 73(10):2464-2471 10.1002/ 1097-0142(19940515)73:10<2464::AID-CNCR2820731004>3.0.CO;2-9 7513601
11. Capurro M Wanless IR Sherman M Deboer G Shi W Miyoshi E Filmus J Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma Gastroenterology 2003, 125(1):89-97. 10.1016/ S0016-5085(03)00689-9 12851874
12. Capurro MI Xiang YY Lobe C Filmus J Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling Cancer Res 2005, 65(14):6245-6254. 10.1158/0008-5472.CAN-04-4244 16024626
13. Suminami Y Kishi F Sekiguchi K Kato H Squamous cell carcinoma antigen is a new member of the serine protease inhibitors Biochem Biophys Res Commun 1991, 181(1):51-58. 10.1016/S0006-291X(05)81380-4 1958219
14. Kato H Torigoe T Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma Cancer 1977, 40(4):1621-1628 10.1002/ 1097-0142(197710)40:4<1621::AID-CNCR2820400435>3.0.CO;2-I 332328
15. Giannelli G Marinosci F Sgarra C Lupo L Dentico P Antonaci S Clinical role of tissue and serum levels of SCCA antigen in hepatocellular carcinoma Int J Cancer 2005, 116(4):579-583. 10.1002/ijc.20847 15825162
16. Giannelli G Antonaci S New frontiers in biomarkers for hepatocellular carcinoma Dig Liver Dis 2006, 38(11):854-859. 10.1016/j.dld.2006.05.007 16782417
17. Grusch M Drucker C Peter-Vorosmarty B Erlach N Lackner A Losert A Macheiner D Schneider WJ Hermann M Groome NP Parzefall W Berger W Grasl-Kraupp B Schulte-Hermann R Deregulation of the activin/follistatin system in hepatocarcinogenesis J Hepatol 2006, 45(5):673-680. 10.1016/ j.jhep.2006.06.014 16935389
18. Brunt EM JCG Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94(9):2467-2474. 10.1111/ j.1572-0241.1999.01377.x 10484010
19. Wilson JF Liver cancer on the rise Ann Intern Med 2005, 142(12 Pt 1):1029-1032. 15968025
20. Giannelli G Fransvea E Trerotoli P Beaugrand M Marinosci F Lupo L Nkontchou G Dentico P Antonaci S Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients Clin Chim Acta 2007, 383(1-2):147-152. 10.1016/ j.cca.2007.05.014 17582392
21. Bruix J Sherman M Management of hepatocellular carcinoma Hepatology 2005, 42(5):1208-1236. 10.1002/hep.20933 16250051
22. Yoon SH Kim JS Song HH Statistical inference methods for detecting altered gene associations Genome informatics 2003, 14:54-63. 15706520
23. Rossmanith W Chabicovsky M Grasl-Kraupp B Peter B Schausberger E Schulte-Hermann R Follistatin overexpression in rodent liver tumors: A possible mechanism to overcome activin growth control Mol Carcinog 2002, 35(1):1-5. 10.1002/mc.10068 12203361
24. Filmus J Capurro M Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma Mol Diagn 2004, 8(4):207-212. 10.2165/ 00066982-200408040-00002 15887976
25. Giannelli G Marinosci F Trerotoli P Volpe A Quaranta M Dentico P Antonaci S SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC Int J Cancer 2005, 117(3):506-509. 10.1002/ijc.21189 15906357
26. Beneduce L Castaldi F Marino M Tono N Gatta A Pontisso P Fassina G Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes Int J Biol Markers 2004, 19(2):155-159. 15255549